About Caladrius

Caladrius Biosciences, Inc. is a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular and autoimmune diseases.

News

September 5, 2019
Caladrius Biosciences to Participate at the Upcoming September Conferences

August 8, 2019
Caladrius Biosciences Reports 2019 Second Quarter and First Six Months Financial Results and Provides Corporate Update

August 7, 2019
Caladrius Biosciences and Cognate BioServices Establish Manufacturing Agreement for Phase 3 Confirmatory Pivotal Clinical Trial of CLBS14 in No-option Refractory Disabling Angina

Events

September 10, 2019
21st Annual Global Investment Conference, Sponsored by H.C. Wainwright

August 8, 2019
Caladrius Biosciences 2nd Quarter 2019 Financial Results and Business Update Conference Call

May 9, 2019
Caladrius Biosciences 1st Quarter 2019 Financial Results and Business Update Conference Call

Sign up to our e-mail list to receive Caladrius announcements.

Technologies & Capabilities

T Regulatory Cell Technology

T Regulatory Cell Technology

CD34 Cell Technology

CD34 Cell Technology